Nutcracker Therapeutics

R&D
JP Morgan 2024 – Sam Deutsch

JP Morgan 2024 – Sam Deutsch

In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervica